IFI16 Partners with KAP1 to Maintain Epstein-Barr Virus Latency.
Cell Line, Tumor
Epstein-Barr Virus Infections
/ genetics
Gene Expression Regulation, Viral
Herpesvirus 4, Human
/ physiology
Heterochromatin
/ genetics
Humans
Nuclear Proteins
/ genetics
Phosphoproteins
/ genetics
Transcription Factors
/ metabolism
Tripartite Motif-Containing Protein 28
/ genetics
Virus Activation
Virus Latency
Epstein-Barr virus
H3K9me3
IFI16
KAP1
TRIM28
ZEBRA
ZTA
herpesvirus
heterochromatin machinery
latency
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
14 09 2022
14 09 2022
Historique:
pubmed:
16
8
2022
medline:
17
9
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
Herpesviruses establish latency to ensure permanent residence in their hosts. Upon entry into a cell, these viruses are rapidly silenced by the host, thereby limiting the destructive viral lytic phase while allowing the virus to hide from the immune system. Notably, although the establishment of latency by the oncogenic herpesvirus Epstein-Barr virus (EBV) requires the expression of viral latency genes, latency can be maintained with a negligible expression of viral genes. Indeed, in several herpesviruses, the host DNA sensor IFI16 facilitated latency via H3K9me3 heterochromatinization. This silencing mark is typically imposed by the constitutive heterochromatin machinery (HCM). The HCM, in an antiviral role, also silences the lytic phase of EBV and other herpes viruses. We investigated if IFI16 restricted EBV lytic activation by partnering with the HCM and found that IFI16 interacted with core components of the HCM, including the KRAB-associated protein 1 (KAP1) and the site-specific DNA binding KRAB-ZFP SZF1. This partnership silenced the EBV lytic switch protein ZEBRA, encoded by the
Identifiants
pubmed: 35969079
doi: 10.1128/jvi.01028-22
pmc: PMC9472614
doi:
Substances chimiques
Heterochromatin
0
Nuclear Proteins
0
Phosphoproteins
0
Transcription Factors
0
IFI16 protein, human
148998-64-5
TRIM28 protein, human
EC 2.3.2.27
Tripartite Motif-Containing Protein 28
EC 2.3.2.27
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0102822Subventions
Organisme : HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
ID : F31 DE031931
Références
Cell Host Microbe. 2013 Nov 13;14(5):591-9
pubmed: 24237704
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Viruses. 2021 May 06;13(5):
pubmed: 34066537
EMBO Rep. 2009 Jul;10(7):769-75
pubmed: 19498464
N Engl J Med. 2004 Mar 25;350(13):1328-37
pubmed: 15044644
J Virol. 2015 Aug;89(15):7506-20
pubmed: 25972554
Annu Rev Pathol. 2019 Jan 24;14:29-53
pubmed: 30125149
PLoS Pathog. 2012 Jan;8(1):e1002498
pubmed: 22291595
mBio. 2019 Jan 22;10(1):
pubmed: 30670617
Microbiol Immunol. 2019 Feb;63(2):51-64
pubmed: 30677166
Elife. 2015 Apr 07;4:
pubmed: 25846574
J Virol. 2018 Jun 29;92(14):
pubmed: 29695433
Nat Immunol. 2010 Nov;11(11):997-1004
pubmed: 20890285
Science. 2022 Jan 21;375(6578):264-265
pubmed: 35025606
Genes Dev. 2002 Apr 15;16(8):919-32
pubmed: 11959841
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
PLoS Pathog. 2014 Nov 06;10(11):e1004503
pubmed: 25375629
J Biol Chem. 2001 Jul 6;276(27):25309-17
pubmed: 11316813
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1722-1730
pubmed: 31919284
Exp Cell Res. 2014 Nov 15;329(1):42-52
pubmed: 25218945
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):E3008-17
pubmed: 23027953
Cell Host Microbe. 2011 May 19;9(5):363-75
pubmed: 21575908
J Virol. 2013 Aug;87(15):8606-23
pubmed: 23720728
Elife. 2019 Nov 04;8:
pubmed: 31682228
J Virol. 2016 Sep 12;90(19):8822-41
pubmed: 27466416
Virol J. 2017 Nov 13;14(1):221
pubmed: 29132393
Nat Biotechnol. 2002 May;20(5):473-7
pubmed: 11981560
PLoS Pathog. 2019 Dec 16;15(12):e1008228
pubmed: 31841561
J Virol. 2013 Nov;87(21):11438-46
pubmed: 23966384
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10558-63
pubmed: 22691496
mBio. 2019 Jul 23;10(4):
pubmed: 31337724
EMBO J. 2005 Feb 23;24(4):800-12
pubmed: 15678104
Nature. 2000 Aug 10;406(6796):593-9
pubmed: 10949293
J Virol. 2010 Jan;84(2):993-1004
pubmed: 19889776
Nucleic Acids Res. 2015 Oct 30;43(19):9097-106
pubmed: 26405197
J Virol. 2008 May;82(10):4706-19
pubmed: 18337569
J Biol Chem. 2015 Oct 30;290(44):26412-21
pubmed: 26354430
J Virol. 2015 Nov;89(22):11347-55
pubmed: 26339061
PLoS Pathog. 2021 Mar 17;17(3):e1009447
pubmed: 33730092
J Virol. 2020 Mar 17;94(7):
pubmed: 31941784
Genes Dev. 2005 Apr 1;19(7):815-26
pubmed: 15774718
J Virol Methods. 2006 Oct;137(1):103-14
pubmed: 16843536
Neurology. 2022 Apr 12;98(15):605-606
pubmed: 35145009
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4492-501
pubmed: 24198334
Cancer Res. 2009 Jul 15;69(14):5681-9
pubmed: 19584288
J Virol. 2021 Jun 10;95(13):e0246620
pubmed: 33853959
PLoS Pathog. 2017 Mar 1;13(3):e1006249
pubmed: 28249048
Cell Metab. 2011 May 4;13(5):517-26
pubmed: 21531334